AUTHORS
Michelle Okwali, MPH, Joshua Bliss, MD, PharmD2, Andriy Derkach, PhD3, Whitney Underwood4, Monica Samtani, RN5, Riley Smith, BS6, Suheil Albert Atallah-Yunes, MD7, Alexander P. Boardman, MD8, Kevin David, MD9, Zachary Epstein-Peterson, MD10, Lorenzo Falchi, MD11, Paola Ghione, MD, MS12, Paul Hamlin, MD13, Steven Horwitz, M.D.14, Anita Kumar, MD15, Jennifer Kimberly Lue, M.D.16, Alison Moskowitz, MD17, Ariela Noy, MD18, Colette Owens, MD19, Maria Lia Palomba, MD20, Mark Roschewski, MD21, Raphael Steiner, MD22, Robert Stuver, MD23, Pallawi Torka, MD24, Andrew Zelenetz, MD25, Jasmine Zain, M.D.26, Gilles Salles I, MD, PhD27, Lee Jones, PhD28, Efrat Luttwak, Luttwak, MD29
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, NY, United States
2 New York Presbyterian, Weill Cornell Medicine, New York, NY, United States
3 Memorial Sloan Kettering Cancer Center, New York, NY, United States
4 Memorial Sloan Kettering Cancer Center, New York, NY, United States
5 Memorial Sloan Kettering Cancer Center, New York, NY, United States
6 Memorial Sloan Kettering Cancer Center, New York, NY, United States
7 Memorial Sloan Kettering Cancer Center, New York, NY, United States
8 Memorial Sloan Kettering Cancer Center, New York, NY, United States
9 Memorial Sloan Kettering Cancer Center, New York, NY, United States
10 Memorial Sloan Kettering Cancer Center, New York, NY, United States
11 Memorial Sloan Kettering Cancer Center, New York, NY, United States
12 Memorial Sloan Kettering Cancer Center, New York, NY, United States
13 Memorial Sloan Kettering Cancer Center, New York, NY, United States
14 Memorial Sloan Kettering Cancer Center, New York, NY, United States
15 Memorial Sloan Kettering Cancer Center, New York, NY, United States
16 Memorial Sloan Kettering Cancer Center, New York, NY, United States
17 Memorial Sloan Kettering Cancer Center, New York, NY, United States
18 Memorial Sloan Kettering Cancer Center, New York, NY, United States
19 Memorial Sloan Kettering Cancer Center, New York, NY, United States
20 Memorial Sloan Kettering Cancer Center, New York, NY, United States
21 Memorial Sloan Kettering Cancer Center, New York, NY, United States
22 Memorial Sloan Kettering Cancer Center, New York, NY, United States
23 Memorial Sloan Kettering Cancer Center, New York, NY, United States
24 Memorial Sloan Kettering Cancer Center, New York, NY, United States
25 Memorial Sloan Kettering Cancer Center, New York, NY, United States
26 Memorial Sloan Kettering Cancer Center, New York, NY, United States
27 Memorial Sloan Kettering Cancer Center, New York, NY, United States
28 City of Hope Cancer Center, Duarte, California, United States
29 Memorial Sloan Kettering Cancer Center, New York, NY, United States
ABSTRACT
Purpose: Peri-diagnosis exercise is linked to improved disease outcomes for several solid tumors but whether the apparent benefit translates to lymphoma and whether the association differs by disease subtype remain unknown. We evaluated the relationship between exercise and time to next treatment (TTNT) and overall survival (OS) across lymphoma subtypes.
Methods: We performed a retrospective analysis of 2,325 patients with lymphoma at a single tertiary cancer center diagnosed between February 2019 and January 2025. Data cutoff used was December 31, 2025. Exercise exposure was collected prospectively at peri-diagnosis using the validated Godin Leisure Time Exercise Questionnaire, administered within 30 days before or after diagnosis via a web application, and quantified in standardized metabolic equivalent of task-hours per week (MET-h/week). Lymphoma diagnoses were classified as indolent (low-grade B-cell lymphomas including CLL/SLL), aggressive large B-cell lymphoma, or classical Hodgkin Lymphoma (cHL). We examined the dose-response relationship between exercise and both TTNT and OS using restricted cubic splines from Cox proportional hazards models. Cox proportional hazards models adjusted for age at diagnosis, sex, and lymphoma subtype were fitted to estimate the impact of exercise on TTNT and OS in complete cases. To reduce confounding, stabilized and truncated propensity score inverse probability of treatment weights (IPTW) were calculated and incorporated into the survival analysis.
Results: Median age was 60 years (IQR: 45-70) and 53.3% were male. Indolent lymphoma was the most common lymphoma subtype (52.9%), followed by aggressive (32.7%) and cHL (14.4%). Median follow-up was 33.2 months (IQR 17.7 – 55.3). The relationship between exercise and TTNT and OS was linear; therefore, exercise was analyzed as a binary variable (0 MET-h/week vs. >0 MET-h/week). After adjusting for age at diagnosis, sex, and lymphoma subtype in the IPTW cohort, >0 MET-h/week was associated with a 39% decrease in the risk of all-cause death compared with 0 MET-h/week (HR 0.61, 95% CI, 0.42 - 0.90). Stratification by lymphoma subtype revealed >0 MET-h/week was significantly associated with longer OS for indolent (HR: 0.47, 95% CI: 0.26 - 0.85) but not aggressive lymphoma (HR 0.73, 95% CI: 0.44 – 1.21) nor cHL (HR 0.40, 95% CI:0.07 – 2.33). There was no significant association between exercise and TTNT in the adjusted-IPTW cohort (HR 0.94, 95% CI: 0.71 – 1.24) or by any subtype.
Conclusion: In this large cohort, exercise was associated with longer OS but not TTNT; on subtype analysis, this association was significant only in indolent lymphoma. This divergence may reflect reductions in non-relapse (e.g., cardiovascular) mortality rather than disease control, although cause of death was unavailable. Analyses incorporating lymphoma-specific parameters and cardiovascular measures are ongoing to further clarify these associations, and our findings require validation in prospective cohorts.
DISCLOSURES
Michelle Okwali, MPH: No relevant conflicts of interest to declare.